Johnson & Johnson Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
Johnson & Johnson (JNJ) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of -$486.00 million for the 12-month period ending 2018-12-30, per its 10-K filed 2020-02-18.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-02-18
- Johnson & Johnson cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-12-30 was -$1.75B.
- Johnson & Johnson cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-09-30 was $0.00.
- Johnson & Johnson cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-07-01 was $0.00.
- Johnson & Johnson cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-04-01 was $1.26B.
- Johnson & Johnson cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2018 was -$486.00M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 6 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 9 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|---|---|---|
| 2018-12-30 | -$1.75B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | -$1.75B derived: sum of 2 quarters · filed 2020-02-18 | -$1.75B derived: sum of 3 quarters · filed 2020-02-18 | -$486.00M 10-K · filed 2020-02-18 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-28 | $0.00 derived: sum of 2 quarters · filed 2019-10-28 | $1.26B 10-Q · filed 2019-10-28 | |
| 2018-07-01 | $0.00 10-Q · filed 2019-07-29 | $1.26B 10-Q · filed 2019-07-29 | ||
| 2018-04-01 | $1.26B 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |